Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

NCT02864953 is registered in ClinicalTrials.gov with Remedy Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02864953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02864953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
Lead sponsor
Remedy Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
August 29, 2018
Completion date
August 18, 2023
Enrollment
535 (actual)
Sites
250

Conditions

As the registry lists them; a condition with its own page is linked.

brain edema, stroke, acute